45 - A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors

Saved in:

Bibliographic Details
Published in	European journal of cancer (1990) Vol. 69; pp. S21 - S22
Main Authors	Razak, A., Gore, L., Britten, C.D., Miller, W.H., Uy, G.L., Nichols, G., Middleton, S., Blotner, S., Zhi, J., Jukofsky, L., Pierceall, W., Higgins, B., Chen, L.C.
Format	Journal Article
Language	English
Published	Elsevier Ltd 01.12.2016
Online Access	Get full text

Loading…

More Information
ISSN:	0959-8049 1879-0852
DOI:	10.1016/S0959-8049(16)32645-4